Curza Inc
Publicly observedSalt Lake City, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Salt Lake City | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Curza Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | VGN5BH7K3DN9 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant9 Jul 2024Publicly observed
NIH SBIR/STTR award: New oral antibiotics focused on treating MDR Gram-negative infections
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant9 Jul 2024Publicly observed
NIH SBIR/STTR award: New oral antibiotics focused on treating MDR Gram-negative infections
USD 1,000,000.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant1 May 2024Publicly observed
NIH SBIR/STTR award: A new class of antibiotic to address Antimicrobial Resistance
USD 999,997.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
- Grant21 Jul 2023Publicly observed
NIH SBIR/STTR award: A New Class of Broad-Spectrum Antibacterial Agents to Treat Multi-Drug Resistant Pathogens
USD 858,436.00 · National Institute of Allergy and Infectious Diseases · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.